Report Highlights

Breathing Disorders Treatment in the U.S.: Market Overview

The U.S. breathing disorders treatment market was valued at USD 18.6 billion in 2024 and is the largest national respiratory therapeutics market in the world. It departs from the global norm because most spending flows through private insurance and Medicare Part D rather than government tenders, while prescription inhalers and biologics are negotiated through pharmacy benefit managers. Durable medical equipment for sleep apnea and home oxygen follows a separate reimbursement track governed by CMS.

Patient demand rests on a large chronic base: about 25 million Americans have asthma, about 16 million have diagnosed COPD, and roughly 30 million adults have obstructive sleep apnea. Revenue concentrates in branded maintenance inhalers and biologics, where net prices reflect rebate negotiations with CVS Caremark, Express Scripts and Optum Rx far more than list prices. Generic albuterol and fluticasone-salmeterol products keep volumes high while compressing margins in older categories.

Growth Drivers Shaping U.S. Breathing Disorder Treatment

The Inflation Reduction Act capped Medicare Part D out-of-pocket spending at USD 2,000 in 2025 and USD 2,100 in 2026, removing the cost ceiling that previously limited uptake of high-list-price maintenance inhalers. With nearly 70 million Medicare enrollees, this cap shifts price sensitivity from patients to plan sponsors, who now accept larger rebates to secure formulary positions.

New approvals are widening the treatable population. Sanofi and Regeneron's Dupixent gained a COPD indication in September 2024, Verona Pharma's Ohtuvayre (ensifentrine) received FDA approval in June 2024 as a non-steroidal maintenance option, and Eli Lilly's Zepbound was approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. Together these launches move pharmacotherapy into a space historically dominated by CPAP devices sold through DME channels.

Market Restraints and Entry Barriers

Pharmacy benefit concentration is the first barrier. CVS Caremark, Express Scripts and Optum Rx administer most commercial formularies and use exclusion lists, step therapy and prior authorization to steer patients toward lower net-price inhalers. A new branded entrant without a rebate agreement risks exclusion from the largest commercial plans, which substantially reduces addressable volume during the first formulary cycle.

Device entry faces tight quality oversight. Philips Respironics entered a consent decree with the U.S. Department of Justice in April 2024 following foam-degradation recalls, restricting new sleep and respiratory device sales in the U.S. until compliance milestones are met. New entrants must obtain FDA 510(k) clearance through CDRH and comply with the Quality Management System Regulation, effective February 2026, which aligns 21 CFR Part 820 with ISO 13485.

Market Opportunities in the U.S.

Eosinophilic COPD represents the largest near-term biologic opportunity. Analyst estimates place roughly 3.5 million U.S. COPD patients in an eosinophilic phenotype suitable for type 2-targeted therapy, and only a small minority currently receive a biologic. Companies with established pulmonology sales forces, including AstraZeneca and GSK, can convert this population through diagnostic bundling with blood eosinophil testing.

Undiagnosed sleep apnea offers the largest volume opportunity. The American Academy of Sleep Medicine has long estimated that most adults with moderate-to-severe obstructive sleep apnea remain undiagnosed, leaving a treatment gap of roughly 20 million people by analyst estimate. Home sleep apnea testing, telehealth referral platforms and specialty pharmacy distribution create entry points for diagnostics firms and pharmacy-channel distributors.

Market at a Glance

Leading Market Participants

• GlaxoSmithKline
• AstraZeneca
• Boehringer Ingelheim
• Sanofi
• Regeneron Pharmaceuticals
• Eli Lilly and Company
• Verona Pharma
• Teva Pharmaceutical Industries
• ResMed
• Philips Respironics

Regulatory and Policy Environment

Drug approvals run through the FDA Center for Drug Evaluation and Research under New Drug Application and Abbreviated New Drug Application pathways, with new molecular entities receiving a standard ten-month review after a sixty-day filing period. Orange Book patent listings govern generic entry, while propellant transitions for metered-dose inhalers fall under EPA oversight of hydrofluorocarbon phase-down authorized by the AIM Act of 2020.

Reimbursement is shaped by the Inflation Reduction Act, which authorizes CMS to negotiate prices for selected Part D drugs with the first negotiated prices effective in 2026. Medicare competitive bidding for DMEPOS items, including CPAP equipment, reshapes supplier contracts in each new round. Entrants must also comply with the federal Anti-Kickback Statute and Physician Payments Sunshine Act reporting administered by CMS.

Long-Term Outlook for U.S. Breathing Care by 2032

By 2032 the market reaches USD 27.4 billion, with growth led by biologics and sleep apnea pharmacotherapy rather than rescue inhalers. Generic erosion of fluticasone-salmeterol and albuterol franchises will compress legacy product revenue, while branded COPD and biologic franchises absorb a growing share of total spend.

Policy risk remains the main variable. Continued IRA negotiation cycles, PBM reform legislation and biosimilar entry for omalizumab will reshape net pricing across the market. Entrants that secure formulary access and diagnostic partnerships now will hold the strongest positions by 2032.